Abstract
Background: Fibromyalgia syndrome (FMS) is a disorder characterized by widespread pain, tenderness, and fatigue. High prevalence marks the syndrome which is considered to reflect altered central pain processing. Fibromyalgia syndrome runs a chronic, non-progressive course, extracting high price owing to impaired quality of life, restricted vocational capacity, and increased health care utilization. Objective: To review current and emerging trends in the treatment of FMS. Methods: A rigorous search of published literature, abstract presentations, and industry provided data was performed. Results/conclusion: The recent FDA approval of pregabalin as a first specific medication for FMS may herald a new era for the development of medications with higher specificity and efficacy for this hitherto frustrating condition.
Original language | English |
---|---|
Pages (from-to) | 53-62 |
Number of pages | 10 |
Journal | Expert Opinion on Emerging Drugs |
Volume | 13 |
Issue number | 1 |
DOIs | |
State | Published - 1 Mar 2008 |
Keywords
- αδ ligands
- Dopamine agonists
- Fibromyalgia
- Growth hormone
- Melatonin
- Reuptake inhibitors
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)